We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go: Stretch investment: Withheld
Chip is one of the fastest-growing Fintech companies in the UK. Chip has built an app that uses the user's banking app to make personalised decisions about their money. Its user base has doubled since its previous fundraising in 2018. The company has 153,000 accounts, and it has processed more than £130m of savings. ChipX is the company's revolutionary returns platform and it has a waiting list of more than 50,000 people. The company is a winner of the British Bank Award, 2 Crowdcube awards, and 1 World Banking Award. It has welcomed many management executives from Funding Circle, Monzo, and Purple Bricks. Chip is now scaling with market-leading returns on ChipX. It aims to build the biggest savings account in the world. With the proceeds, the company will double its team and expand ChipX in the €10 trillion European savings market.
days to go: Expired investment: £3,768,260
With support from the founders of Bulldog Skincare, Zoopla and Love Film, VITL's aim is to improve the nation's health by offering vitamin packs that are fully personalised to the customer. VITL uses artificial intelligence to decipher which nutrients a person needs to ensure a healthy lifestyle. Effectively cutting out the cost of a private nutritionist.

Pitch Rated

44%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £908,950
Cambridge Nutraceuticals develop and sell healthcare supplements that are proven to provide health benefits. Their products ar ecurrently on shelves in a number of the large high street retailers such as Holland & Barrett and Boots.
days to go: Expired investment: £1,077,710
A web-based location experience platform for businesses to market their content for their target audience by users visiting physical locations to view digital content. Landmrk's service is currently used by travel, entertainment and retail industries and allows businesses to provide 'rewards' when customers reach the location. Revenue is primarily generated from marketing agencies and businesses licensing the platform on a monthly, quartely or annual basis.
days to go: Expired investment: £519,364
Myn is an innovative source-to-pay platform driven by AI, aiming to establish a seamless network connecting companies, workers, and recruiters. Their end-to-end solution encompasses intelligent talent sourcing, self-service talent acquisition, fully funded payrolling services, digital compliance solutions, job boards, and enticing employee benefits.
days to go: Expired investment: £939,520
An artificially intelligent web-based app for stock market investors to potentially increase their returns. Butterwire's platform aims to solve three common challenges more than 1 million UK investors face: finding high-return opportunities, minimising risk and being aware of sudden market fluctuations.
days to go: Expired investment: Withheld
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph